Go Pro
→ Your withdrawal order could cost you in taxes (From SmartAsset) (Ad)tc pixel Free HEMO Stock Alerts

Hemogenyx Pharmaceuticals (HEMO) Competitors

Hemogenyx Pharmaceuticals logo
GBX 590 +2.00 (+0.34%)
As of 11:58 AM Eastern
Compare

HEMO vs. CIR, TILS, VSN, SCLP, and MPH

Should you buy Hemogenyx Pharmaceuticals stock or one of its competitors? Hemogenyx Pharmaceuticals's main competitors and comparable companies include Circassia Group (CIR), Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), and Mereo BioPharma Group plc (MPH.L) (MPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Hemogenyx Pharmaceuticals compare to Circassia Group?

Circassia Group (LON:CIR) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Circassia Group has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Circassia Group£27.90M0.00N/A£0.01N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

Circassia Group's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Circassia GroupN/A N/A N/A
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

In the previous week, Circassia Group's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Circassia Group Neutral
Hemogenyx Pharmaceuticals Neutral

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Circassia Group beats Hemogenyx Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Tiziana Life Sciences?

Hemogenyx Pharmaceuticals (LON:HEMO) and Tiziana Life Sciences (LON:TILS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Tiziana Life Sciences' return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Tiziana Life Sciences N/A N/A N/A

Tiziana Life Sciences has lower revenue, but higher earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A

In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Tiziana Life Sciences'average media sentiment score.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Tiziana Life Sciences Neutral

Summary

Hemogenyx Pharmaceuticals beats Tiziana Life Sciences on 4 of the 7 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Verseon?

Verseon (LON:VSN) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VerseonN/AN/AN/A-£14.30N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

In the previous week, Verseon's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Verseon Neutral
Hemogenyx Pharmaceuticals Neutral

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Verseon's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
VerseonN/A N/A N/A
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

Summary

Verseon and Hemogenyx Pharmaceuticals tied by winning 3 of the 6 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Scancell?

Scancell (LON:SCLP) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Scancell has a beta of 0.687, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.501, suggesting that its share price is 50% more volatile than the broader market.

1.5% of Scancell shares are held by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 15.5% of Scancell shares are held by insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Scancell-116.98% 90.29% -45.28%
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scancell£4.71M21.33-£6.75M-£0.55N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

In the previous week, Scancell had 1 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 1 mentions for Scancell and 0 mentions for Hemogenyx Pharmaceuticals. Scancell's average media sentiment score of 0.49 beat Hemogenyx Pharmaceuticals' score of 0.00 indicating that Scancell is being referred to more favorably in the media.

Company Overall Sentiment
Scancell Neutral
Hemogenyx Pharmaceuticals Neutral

Summary

Scancell beats Hemogenyx Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Mereo BioPharma Group plc (MPH.L)N/A N/A N/A
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

In the previous week, Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Mereo BioPharma Group plc (MPH.L) Neutral
Hemogenyx Pharmaceuticals Neutral

Summary

Mereo BioPharma Group plc (MPH.L) beats Hemogenyx Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

Get Hemogenyx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HEMO vs. The Competition

Export
MetricHemogenyx PharmaceuticalsBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£40.12M£4.06B£7.40B£2.92B
Dividend YieldN/A3.61%2.53%6.17%
P/E Ratio-3.4611.42272.19367.32
Price / SalesN/A1,369.91631.7683,741.35
Price / Cash2.05108.3779.8927.89
Price / Book2,394.8816.8813.147.02
Net Income-£6.89K-£22.76M£3.47B£5.89B
7 Day Performance-4.53%1.55%1.38%0.89%
1 Month Performance-18.84%11.70%8.62%3.27%
1 Year Performance214.67%56.88%25.90%22.28%

Hemogenyx Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 590
+0.3%		N/A+237.5%£40.12MN/AN/A14
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11
VSN
Verseon
N/AN/AN/AN/A£112.24MN/AN/AN/A
SCLP
Scancell
N/AGBX 9.64
-1.7%		N/A-5.4%£100.00M£4.71MN/A51

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:HEMO) was last updated on 8/26/2026 by MarketBeat.com Staff.
From Our Partners
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Jeff Brown and Marc Chaikin's latest AI prediction explained
Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...
Brownstone Research | Sponsoredtc pixel
Buy this stock today
Most tech companies skip dividends entirely. This one doesn't, paying shareholders like clockwork while flying...
Chaikin Analytics | Sponsoredtc pixel